ARTURO MD MOLINA, the Chief Medical Officer of $PTGX, sold 9,514 shares of the company on 01-20-2026 for an estimated $784,714. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.9% of their shares of this class of stock. Following this trade, they now own 97,266 shares of this class of $PTGX stock.
$PTGX Insider Trading Activity
$PTGX insiders have traded $PTGX stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $PTGX stock by insiders over the last 6 months:
- DINESH V PH D PATEL (President and CEO) has made 0 purchases and 3 sales selling 62,373 shares for an estimated $4,370,900.
- WILLIAM D. WADDILL has made 0 purchases and 4 sales selling 20,000 shares for an estimated $1,473,480.
- ARTURO MD MOLINA (Chief Medical Officer) has made 0 purchases and 2 sales selling 12,226 shares for an estimated $1,014,610.
- ASIF ALI (Chief Financial Officer) sold 8,588 shares for an estimated $708,338
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PTGX Hedge Fund Activity
We have seen 131 institutional investors add shares of $PTGX stock to their portfolio, and 147 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP removed 1,530,208 shares (-47.1%) from their portfolio in Q3 2025, for an estimated $101,651,717
- MARSHALL WACE, LLP added 1,085,564 shares (+inf%) to their portfolio in Q3 2025, for an estimated $72,114,016
- WELLINGTON MANAGEMENT GROUP LLP added 870,708 shares (+83.9%) to their portfolio in Q3 2025, for an estimated $57,841,132
- JANUS HENDERSON GROUP PLC added 653,993 shares (+146.4%) to their portfolio in Q3 2025, for an estimated $43,444,754
- BVF INC/IL removed 650,125 shares (-20.2%) from their portfolio in Q3 2025, for an estimated $43,187,803
- UBS GROUP AG removed 605,243 shares (-24.2%) from their portfolio in Q3 2025, for an estimated $40,206,292
- HOLOCENE ADVISORS, LP removed 530,326 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $35,229,556
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PTGX Analyst Ratings
Wall Street analysts have issued reports on $PTGX in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/05/2026
- Citigroup issued a "Buy" rating on 11/10/2025
- Citizens issued a "Market Outperform" rating on 11/07/2025
- Barclays issued a "Overweight" rating on 11/07/2025
- JP Morgan issued a "Overweight" rating on 11/07/2025
- BTIG issued a "Buy" rating on 10/28/2025
- Wedbush issued a "Outperform" rating on 10/28/2025
To track analyst ratings and price targets for $PTGX, check out Quiver Quantitative's $PTGX forecast page.
$PTGX Price Targets
Multiple analysts have issued price targets for $PTGX recently. We have seen 10 analysts offer price targets for $PTGX in the last 6 months, with a median target of $84.0.
Here are some recent targets:
- Srikripa Devarakonda from Truist Securities set a target price of $110.0 on 01/05/2026
- Etzer Darout from Barclays set a target price of $108.0 on 12/17/2025
- Geoff Meacham from Citigroup set a target price of $115.0 on 12/08/2025
- Jonathan Wolleben from Citizens set a target price of $102.0 on 11/07/2025
- Brian Cheng from JP Morgan set a target price of $81.0 on 11/07/2025
- Julian Harrison from BTIG set a target price of $82.0 on 10/28/2025
- Yun Zhong from Wedbush set a target price of $86.0 on 10/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
